Expanding scope of stimulants to better treat attention deficit hyperactivity disorder

Expanding scope of stimulants to better treat attention deficit hyperactivity disorder

first_imgReviewed by Kate Anderton, B.Sc. (Editor)May 22 2019A comprehensive new review of the expanding scope of stimulants available to treat attention deficit hyperactivity disorder (ADHD) serves as a valuable guide to clinicians as they choose from among the many new drug formulations and technologies available to treat this complex disorder. The wide-ranging review is published in the Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.Entitled “New Formulations of Stimulants: An Update for Clinicians,” the article was coauthored by Ronald Steingard, MD, Child Mind Institute (New York, NY), Sarper Taskiran, MD, Child Mind Institute and Koc University School of Medicine (Istanbul, Turkey), Mark Stein, PhD, University of Washington (Seattle), Daniel Connor, MD, University of Connecticut School of Medicine (Farmington), and John Markowitz, PharmD, University of Florida (Gainesville).Related StoriesChaos in the house and asthma in children – the connectionExperts release scientific statement on predicting survival for cardiac arrest survivorsAntibiotic combination effective against drug-resistant PseudomonasThe manuscript is designed to provide a guide to newer stimulant formulations. Following a brief review of ADHD and the two most common stimulants used for treatment – amphetamine and methylphenidate — the authors focus on the rapid growth in new formulations of these drugs. They explain novel delivery systems such as orally dissolving tablets (ODT), chewable tablets, extended release (ER) liquid formulations, transdermal patches, and novel “beaded” technology and suggest how to use them in clinical practice. In addition, the authors look at the advances in our knowledge regarding individual variability with regards to response and metabolism that has contributed to a more nuanced approach to treatment.Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York, states: “New Formulations of Stimulants: An Update for Clinicians,’ written by Ron Steingard, MD and colleagues is an essential guide for pediatricians, pediatric neurologists, and child and adolescent psychiatrists who treat children and teens with ADHD.” Source:Mary Ann Liebert, Inc.last_img

Leave a Reply

Your email address will not be published. Required fields are marked *

Message *
Name*
Email *